MRK · News · 20261113N

Regulatory Approval Milestones

Merck & Co., Inc. · 2026-11-13 · Importance 34 · Surprise 42 · In source text

The European Medicines Agency’s CHMP recommended expanding ENFLONSIA (clesrovimab) to prevent RSV lower respiratory tract disease in children up to 24 months old who remain at increased risk of severe disease through their second RSV season. The recommendation will be reviewed by the European Commission for authorization in the EU, Iceland, Liechtenstein and Norway, with a final decision expected within two months. ENFLONSIA is already approved in numerous countries for infants during their first RSV season.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
revenuepositiveprobable—The positive CHMP opinion for Merck's WELIREG plus lenvatinib was based on positive progression-free survival results from the Phase 3…
revenuepositiveprobable—The EMA's CHMP recommended expanding Merck's ENFLONSIA indication to prevent RSV lower respiratory tract disease in children up to 24…